{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T09:04:17Z","timestamp":1758704657194,"version":"3.41.2"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province","award":["(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904"],"award-info":[{"award-number":["(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904","(JBZX-201904"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00277-025-06432-9","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:18:46Z","timestamp":1748578726000},"page":"3495-3504","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multi-courses of blinatumomab combined with reduced dose chemotherapy has been successfully used in chemo-intolerant middle to high-risk pediatric B-ALL patients with invasive fungal disease"],"prefix":"10.1007","volume":"104","author":[{"given":"En-Min","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongmin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shupeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heping","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diying","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"6432_CR1","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00277-018-3252-6","volume":"97","author":"R Di Blasi","year":"2018","unstructured":"Di Blasi R, Cattaneo C, Lewis RE, Tumbarello M, Angelici L, Dragonetti G et al (2018) Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012\/B ALL). Ann Hematol 97:791\u2013798. https:\/\/doi.org\/10.1007\/s00277-018-3252-6","journal-title":"Ann Hematol"},{"key":"6432_CR2","doi-asserted-by":"publisher","first-page":"5579","DOI":"10.1200\/JCO.23.01286","volume":"41","author":"R Pieters","year":"2023","unstructured":"Pieters R, Mullighan CG, Hunger SP (2023) Advancing diagnostics and therapy to reach universal cure in childhood ALL. J Clin Oncol 41:5579\u20135591. https:\/\/doi.org\/10.1200\/JCO.23.01286","journal-title":"J Clin Oncol"},{"key":"6432_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3389\/fmicb.2019.00681","volume":"10","author":"T Lehrnbecher","year":"2019","unstructured":"Lehrnbecher T, Schoning S, Poyer F, Georg J, Becker A, Gordon K et al (2019) Incidence and outcome of invasive fungal diseases in children with hematological malignancies and\/or allogeneic hematopoietic stem cell transplantation: results of a prospective multicenter study. Front Microbiol 10:681. https:\/\/doi.org\/10.3389\/fmicb.2019.00681","journal-title":"Front Microbiol"},{"key":"6432_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12933-021-01252-3","volume":"20","author":"SH Park","year":"2021","unstructured":"Park SH, Belcastro E, Hasan H, Matsushita K, Marchandot B, Abbas M et al (2021) Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of Gliflozins. Cardiovasc Diabetol 20:65. https:\/\/doi.org\/10.1186\/s12933-021-01252-3","journal-title":"Cardiovasc Diabetol"},{"key":"6432_CR5","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/s1473-3099(19)30312-3","volume":"19","author":"OA Cornely","year":"2019","unstructured":"Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B et al (2019) Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in Cooperation with the mycoses study group education and research consortium. Lancet Infect Dis 19:e405\u2013e421. https:\/\/doi.org\/10.1016\/s1473-3099(19)30312-3","journal-title":"Lancet Infect Dis"},{"key":"6432_CR6","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","volume":"325","author":"PA Brown","year":"2021","unstructured":"Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ et al (2021) Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on Disease-Free survival in children, adolescents, and young adults with first relapse of B-Cell acute lymphoblastic leukemia: A randomized clinical trial. JAMA 325:833\u2013842. https:\/\/doi.org\/10.1001\/jama.2021.0669","journal-title":"JAMA"},{"key":"6432_CR7","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2021.0987","volume":"325","author":"F Locatelli","year":"2021","unstructured":"Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T et al (2021) Effect of blinatumomab vs chemotherapy on Event-Free survival among children with High-risk First-Relapse B-Cell acute lymphoblastic leukemia: A randomized clinical trial. JAMA 325:843\u2013854. https:\/\/doi.org\/10.1001\/jama.2021.0987","journal-title":"JAMA"},{"key":"6432_CR8","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/jco.2016.67.3301","volume":"34","author":"A von Stackelberg","year":"2016","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C et al (2016) Phase i\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol 34:4381\u20134389. https:\/\/doi.org\/10.1200\/jco.2016.67.3301","journal-title":"J Clin Oncol"},{"key":"6432_CR9","doi-asserted-by":"publisher","first-page":"a019612","DOI":"10.1101\/cshperspect.a019612","volume":"5","author":"A Verma","year":"2014","unstructured":"Verma A, W\u00fcthrich M, Deepe G, Klein B (2014) Adaptive immunity to fungi. Cold Spring Harb Perspect Med 5:a019612. https:\/\/doi.org\/10.1101\/cshperspect.a019612","journal-title":"Cold Spring Harb Perspect Med"},{"key":"6432_CR10","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE et al (2020) Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of Cancer and the mycoses study group education and research consortium. Clin Infect Dis 71:1367\u20131376. https:\/\/doi.org\/10.1093\/cid\/ciz1008","journal-title":"Clin Infect Dis"},{"key":"6432_CR11","doi-asserted-by":"publisher","first-page":"7468","DOI":"10.1038\/s41467-023-43171-9","volume":"14","author":"H Chen","year":"2023","unstructured":"Chen H, Gu M, Liang J, Song H, Zhang J, Xu W et al (2023) Minimal residual disease detection by next-generation sequencing of different Immunoglobulin gene rearrangements in pediatric B-ALL. Nat Commun 14:7468. https:\/\/doi.org\/10.1038\/s41467-023-43171-9","journal-title":"Nat Commun"},{"key":"6432_CR12","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1097\/mph.0000000000001690","volume":"42","author":"S Ramanathan","year":"2020","unstructured":"Ramanathan S, Kate S, Kembhavi S, Cheriyalinkal Parambil B, K CA, Bhat V et al (2020) A retrospective analysis of invasive fungal diseases (IFD) of the central nervous system in children with lymphoid malignancies. J Pediatr Hematol Oncol 42:e202\u2013e206. https:\/\/doi.org\/10.1097\/mph.0000000000001690","journal-title":"J Pediatr Hematol Oncol"},{"key":"6432_CR13","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/jac\/dkac060","volume":"77","author":"DK Yeoh","year":"2022","unstructured":"Yeoh DK, Haeusler GM, McMullan BJ, Butters C, Bryant PA, Clark JE et al (2022) Antifungal use in children with acute leukaemia: state of current evidence and directions for future research. J Antimicrob Chemother 77:1508\u20131524. https:\/\/doi.org\/10.1093\/jac\/dkac060","journal-title":"J Antimicrob Chemother"},{"key":"6432_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40360-015-0012-2","volume":"16","author":"E Ersvaer","year":"2015","unstructured":"Ersvaer E, Brenner AK, Vet\u00e5s K, Reikvam H, Bruserud \u00d8 (2015) Effects of cytarabine on activation of human T cells\u2013 cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid. BMC Pharmacol Toxicol 16:12. https:\/\/doi.org\/10.1186\/s40360-015-0012-2","journal-title":"BMC Pharmacol Toxicol"},{"key":"6432_CR15","doi-asserted-by":"publisher","first-page":"e28922","DOI":"10.1002\/pbc.28922","volume":"68","author":"R Sutton","year":"2021","unstructured":"Sutton R, Pozza LD, Khaw SL, Fraser C, Revesz T, Chamberlain J et al (2021) Outcomes for Australian children with relapsed\/refractory acute lymphoblastic leukaemia treated with blinatumomab. Pediatr Blood Cancer 68:e28922. https:\/\/doi.org\/10.1002\/pbc.28922","journal-title":"Pediatr Blood Cancer"},{"key":"6432_CR16","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/bjh.18314","volume":"198","author":"DK Yeoh","year":"2022","unstructured":"Yeoh DK, Blyth CC, Kotecha RS (2022) Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease. Br J Haematol 198:887\u2013892. https:\/\/doi.org\/10.1111\/bjh.18314","journal-title":"Br J Haematol"},{"key":"6432_CR17","doi-asserted-by":"publisher","unstructured":"(2022) [Report of Chinese Children\u2019s Cancer Group acute lymphoblastic leukemia 2015 multicenter study]. Zhonghua Er Ke Za Zhi 60:1002\u20131010. https:\/\/doi.org\/10.3760\/cma.j.cn112140-20220719-00895","DOI":"10.3760\/cma.j.cn112140-20220719-00895"},{"key":"6432_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12885-020-07752-x","volume":"21","author":"XY Li","year":"2021","unstructured":"Li XY, Li JQ, Luo XQ, Wu XD, Sun X, Xu HG et al (2021) Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol. BMC Cancer 21:59. https:\/\/doi.org\/10.1186\/s12885-020-07752-x","journal-title":"BMC Cancer"},{"key":"6432_CR19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.7499\/j.issn.1008-8830.2211041","volume":"25","author":"XF Zhu","year":"2023","unstructured":"Zhu XF (2023) [Optimized treatment of childhood B-lineage acute lymphoblastic leukemia]. Zhongguo Dang Dai Er Ke Za Zhi 25:344\u2013349. https:\/\/doi.org\/10.7499\/j.issn.1008-8830.2211041","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"6432_CR20","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Fo\u00e0","year":"2020","unstructured":"Fo\u00e0 R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC et al (2020) Dasatinib-Blinatumomab for Ph-Positive acute lymphoblastic leukemia in adults. N Engl J Med 383:1613\u20131623. https:\/\/doi.org\/10.1056\/NEJMoa2016272","journal-title":"N Engl J Med"},{"key":"6432_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/1078155219829534","volume":"26","author":"AC Robinson","year":"2020","unstructured":"Robinson AC, Marini BL, Pettit KM, Perissinotti AJ (2020) Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction. J Oncol Pharm Pract 26:200\u2013205. https:\/\/doi.org\/10.1177\/1078155219829534","journal-title":"J Oncol Pharm Pract"},{"key":"6432_CR22","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1200\/jco.21.01766","volume":"40","author":"AS Advani","year":"2022","unstructured":"Advani AS, Moseley A, O\u2019Dwyer KM, Wood BL, Fang M, Wieduwilt MJ et al (2022) SWOG 1318: A phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia Chromosome-Negative B-Cell acute lymphoblastic leukemia. J Clin Oncol 40:1574\u20131582. https:\/\/doi.org\/10.1200\/jco.21.01766","journal-title":"J Clin Oncol"},{"key":"6432_CR23","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","volume":"131","author":"B Wood","year":"2018","unstructured":"Wood B, Wu D, Crossley B, Dai Y, Williamson D, Gawad C et al (2018) Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood 131:1350\u20131359. https:\/\/doi.org\/10.1182\/blood-2017-09-806521","journal-title":"Blood"},{"key":"6432_CR24","doi-asserted-by":"publisher","first-page":"e27265","DOI":"10.1002\/pbc.27265","volume":"65","author":"MJ Oberley","year":"2018","unstructured":"Oberley MJ, Gaynon PS, Bhojwani D, Pulsipher MA, Gardner RA, Hiemenz MC et al (2018) Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia. Pediatr Blood Cancer 65:e27265. https:\/\/doi.org\/10.1002\/pbc.27265","journal-title":"Pediatr Blood Cancer"},{"key":"6432_CR25","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41375-021-01199-0","volume":"35","author":"S Hirabayashi","year":"2021","unstructured":"Hirabayashi S, Butler ER, Ohki K, Kiyokawa N, Bergmann AK, Moricke A et al (2021) Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte Di Legno childhood ALL working group. Leukemia 35:3272\u20133277. https:\/\/doi.org\/10.1038\/s41375-021-01199-0","journal-title":"Leukemia"},{"key":"6432_CR26","doi-asserted-by":"publisher","first-page":"107327482311827","DOI":"10.1177\/10732748231182787","volume":"30","author":"L Zhu","year":"2023","unstructured":"Zhu L, Bai W, Cheng Q, Fang J (2023) ZNF384-Related fusion genes in acute lymphoblastic leukemia. Cancer Control 30:10732748231182787. https:\/\/doi.org\/10.1177\/10732748231182787","journal-title":"Cancer Control"},{"key":"6432_CR27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/2643-3230.Bcd-20-0229","volume":"2","author":"S Jeha","year":"2021","unstructured":"Jeha S, Choi J, Roberts KG, Pei D, Coustan-Smith E, Inaba H et al (2021) Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. Blood Cancer Discov 2:326\u2013337. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-20-0229","journal-title":"Blood Cancer Discov"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06432-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06432-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06432-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T08:00:26Z","timestamp":1753171226000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06432-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["6432"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06432-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from each patient\u2019s parent for their clinical information to be used for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}